These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8226403)

  • 21. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
    Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
    Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation, characterization, and evaluation of amphotericin B-loaded MPEG-PCL-g-PEI micelles for local treatment of oral
    Zhou L; Zhang P; Chen Z; Cai S; Jing T; Fan H; Mo F; Zhang J; Lin R
    Int J Nanomedicine; 2017; 12():4269-4283. PubMed ID: 28652732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case-control study of amphotericin B in a triglyceride fat emulsion versus conventional amphotericin B in patients with AIDS.
    Manfredi R; Chiodo F
    Pharmacotherapy; 1998; 18(5):1087-92. PubMed ID: 9758320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes.
    Forster D; Washington C; Davis SS
    J Pharm Pharmacol; 1988 May; 40(5):325-8. PubMed ID: 2899626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective toxicity of the polyene antibiotics and their methyl ester derivatives.
    Chen WC; Sud IJ; Chou DL; Feingold DS
    Biochem Biophys Res Commun; 1977 Jan; 74(2):480-7. PubMed ID: 319797
    [No Abstract]   [Full Text] [Related]  

  • 27. Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis.
    Chavanet PY; Garry I; Charlier N; Caillot D; Kisterman JP; D'Athis M; Portier H
    BMJ; 1992 Oct; 305(6859):921-5. PubMed ID: 1458072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles.
    Brajtburg J; Elberg S; Kobayashi GS; Medoff G
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2415-6. PubMed ID: 2088196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
    Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
    Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.
    El-Azizi M; Farag N; Khardori N
    Ann Clin Microbiol Antimicrob; 2015 Apr; 14():21. PubMed ID: 25885806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the toxicity of a new lipid complex formulation of amphotericin B.
    Larabi M; Pages N; Pons F; Appel M; Gulik A; Schlatter J; Bouvet S; Barratt G
    J Antimicrob Chemother; 2004 Jan; 53(1):81-8. PubMed ID: 14657087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
    Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
    Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions of liposomal amphotericin B with extracellular and intracellular Candida albicans.
    van Etten EW; Chander HR; Snijders SV; Bakker-Woudenberg IA
    J Antimicrob Chemother; 1995 Dec; 36(6):961-74. PubMed ID: 8821595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro studies on liposomal formulations of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME).
    Cybulska B; Kupczyk K; Szlinder-Richert J; Borowski E
    Acta Biochim Pol; 2002; 49(1):67-75. PubMed ID: 12136958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antifungal and Mucoadhesive Properties of an Orally Administered Chitosan-Coated Amphotericin B Nanostructured Lipid Carrier (NLC).
    Ling JTS; Roberts CJ; Billa N
    AAPS PharmSciTech; 2019 Mar; 20(3):136. PubMed ID: 30838459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B- and folic acid-induced nephropathies in developing rats.
    Kavlock RJ; Rehnberg BF; Rogers EH
    Toxicol Appl Pharmacol; 1985 Dec; 81(3 Pt 1):407-15. PubMed ID: 4082191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.
    Perkins WR; Minchey SR; Boni LT; Swenson CE; Popescu MC; Pasternack RF; Janoff AS
    Biochim Biophys Acta; 1992 Jun; 1107(2):271-82. PubMed ID: 1504072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined effect of liposomal and conventional amphotericin B in a mouse model of systemic infection with Candida albicans.
    Kretschmar M; Bertsch T; Nichterlein T
    J Chemother; 2004 Jun; 16(3):255-8. PubMed ID: 15330321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures.
    Shadkhan Y; Segal E; Bor A; Gov Y; Rubin M; Lichtenberg D
    J Antimicrob Chemother; 1997 May; 39(5):655-8. PubMed ID: 9184368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.